The International Clearinghouse for Birth Surveillance and Research, formerly known as International Clearinghouse of Birth Defects Monitoring Systems, consists of 40 registries worldwide that collaborate in monitoring 40 types of birth defects. Clearinghouse activities include the sharing and joint monitoring of birth defect data, epidemiologic and public health research, and capacity building, with the goal of reducing disease and promoting healthy birth outcomes through primary prevention.
We discuss 3 of these activities: the collaborative assessment of the potential teratogenicity of first-trimester use of medications (the MADRE project), an example of the intersection of surveillance and research; the international databases of people with orofacial clefts, an example of the evolution from surveillance to outcome research; and the study of genetic polymorphisms, an example of collaboration in public health genetics. ( The Clearinghouse now includes 40 registries from developed and developing countries that jointly monitor 40 birth defects. In addition to monitoring, activities include public health research and capacity building to reduce disease and promote healthy outcomes through primary prevention. Specifically, the Clearinghouse monitors for teratogenicity of medications, an example of the intersection of surveillance and research; manages an international database of people with orofacial clefts, to promote outcome research; and has completed an international study of genetic polymorphisms of folate genes, to promote international public health genetic research.
Such international collaboration advances crucial public health goals related to healthy pregnancy and child survival. Sustained recognition and support of collaborating programs from governmental and international organizations is critically important to further these goals in developed and developing countries.
YEARS OF INTERNATIONAL COLLABORATION
The Clearinghouse began as a response to the threat of unrecognized teratogens. When they met in 1974 in Helsinki, Finland, in the aftermath of the thalidomide epidemic, representatives of birth defect registries from the Americas and Europe agreed to share and jointly monitor birth defect data in a regular and timely manner to help prevent such tragedies in the future. 1 To do so, they established the Clearinghouse with seed monies from the March of Dimes. Since then, the Clearinghouse has evolved in size and scope. Forty registries (up from 10 in 1974) now collaborate to monitor 40 types of birth defects (up from 22 in 1974) among 3.5 million yearly births. 2 The Clearinghouse has also developed a head office and coordinating center, the International Center on Birth Defects (ICBD), with seed monies from nongovernmental and governmental organizations (mainly from Norway, Italy, the European Commission, and the United States) and has established official relations with several like-minded international bodies including other birth defect networks and the World Health Organization. As a result, the Clearinghouse has been able not only to continue the joint exchange and monitoring of birth defect data but also to conduct epidemiological and public health research as well as help new countries develop and improve surveillance systems (Table 1) . These 3 focus areas-surveillance, research, and capacity building-share the goal of reducing disease and promoting healthy outcomes through primary prevention. Therefore, they represent the natural evolution of the original mission of the Clearinghouse.
We selected 3 ongoing Clearinghouse activities, 1 in each of these 3 areas, as examples of creative and crosscutting efforts that 
SEARCHING INTERNATIONAL REGISTRIES FOR UNSUSPECTED TERATOGENS
Maternal use of medication has accounted for clusters of birth defects in the past, such as those related to thalidomide 3 and, more recently, retinoic acid. 4 Moreover, the safety during pregnancy of many medications has not been conclusively established. Because women frequently use medications during the first months of pregnancy, 5 often before the pregnancy is recognized, even small teratogenic risks can result in many infants being affected. Registries of congenital malformations can provide crucial data to identify teratogenic effects of medications. The analytic approach depends on the design of the registry, which in the Clearinghouse typically falls into 1 of 3 main types. In the first, the registry is built on the medical registration of all births, as occurs in the Nordic countries in Europe. The Swedish Medical Birth Registry, for example, contains prospectively collected information on drug use as reported by the pregnant woman at her first visit to the antenatal care system, 6 and this information has been used for evaluation of pregnancy outcome after exposure to drugs. 7, 8 The second type of registry is designed as an ongoing case-control study. Each case is matched with a control, which is often defined as the next nonmalformed birth of the same sex as the case. The third type, exemplified by most registries, includes cases but no controls and relies on the completion of special notification forms that list the malformations and medications used during the first trimester. The first 2 types of registries lend themselves naturally to the study of associations between malformations and maternal use of medication; the third type of registry, which enrolls only cases, may also be helpful in this regard. The Clearinghouse has thus implemented the MADRE project as a collaborative study among several registries of the third type, the main features of which are summarized in Table 2 . 9 In MADRE, medications are cross-tabulated against malformations and a 2-by-2 table is constructed for each combination of medication and malformation. An infant is defined as a case infant if it has the malformation in question and as a control infant otherwise. An infant is defined as exposed if the mother used the drug in question during the first trimester and as unexposed otherwise. If exposures and malformations are unrelated, drug types and malformation types should be randomly distributed, and deviations from this distribution will show up as increased odds 
Goal
Screen for potential teratogenicity of medications Approach Case-only study of cases of birth defects following reported exposure to maternal medication use during first trimester of pregnancy; all cases are malformed and all cases were exposed to some medication; analysis is through a modified case-affected control approach, stratified by registry Current data More than 15 000 cases of birth defects from 12 registries
Selected findings (antiseizure medications) Confirmed classical associations: phenobarbital with oral clefts and heart defects; valproic acid with spina bifida, hypospadias, and heart defects; and carbamazepine and heart defects Testing associations suggested in literature: evaluated and confirmed the reported association between valproic acid and craniosynostosis
Evolution
Refine classification according to pathogenetic mechanisms; assess specific risks for multiple congenital anomalies; focus on selected major defects (heart defect subtypes, gastroschisis); increase registry participation ratios. Such deviations can be used to screen for associations that deserve further study. This approach has limitations and strengths. By design, the approach lends itself to identifying differential effects of medications on malformations, so that drugs that increase risk equally for all birth defects will be missed. Classification of medications and malformations is also crucial. In MADRE, malformations are coded according to the International Classification of Diseases, Ninth Revision system adapted by the British Pediatric Association, 10 and medications are coded according to the Anatomical Therapeutic Chemical system.
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These systems have limitations that are being circumvented by further lumping and splitting of categories. International variability in the use of medications and in the occurrence of malformations is also a concern. In MADRE, all analyses are stratified by registry and evaluated for heterogeneity.
The main strength of MADRE is that it uses available data as an adjunct tool to screen for teratogens at low cost. Associations thus identified should be further assessed in other data sets. The international setting and the large sample size obtainable from collaborating registries also lead to improved statistical power and provide, to some extent, internal indicators of consistency. For example, an association is increasingly unlikely to be because of chance if it occurs simultaneously in different registries. Finally, because all cases are affected, differential recall of medication use is less of a concern than in a case-unaffected control setting.
The MADRE project now includes more than 15 000 cases. The analyses have detected several associations, both known (e.g., valproic acid and spina bifida) and new. New associations are considered as hypotheses to be tested on further samples, as was the case for the association between corticosteroids and orofacial clefts. The first suggestion for such an association was reported in 1994, 9 and 3 epidemiological studies since have confirmed a weak association [12] [13] [14] ;
the association was confirmed in 2003 by the MADRE data. 15 The MADRE database also is used to test associations as they appear in the literature. For example, we confirmed the suggested association between valproic acid and craniosynostosis (mainly trigonocephaly) 16 
and assigned its coordination to the ICBD, the head office of the Clearinghouse (Table 3) .
The international database properly is a set of databases that vary in topic and aims. At present, the efforts of IDCFA focus on developing the "International Perinatal Databases of Typical Orofacial Clefts" (IPDTOC). As of July 2004, 56 registries had joined the data collecting effort, representing 36 countries: 21 in Europe; 12 in North, Central, and South America and the Caribbean; and Japan, South Africa, and the United Arab Emirates. Currently, data are available from more than 3.5 million births, and registries are expected to update their submissions yearly.
Although participation requires additional effort on their part, contributing programs, though at times strained for resources, can benefit in many ways. First, they benefit from increased visibility, nationally and internationally, as their data are used in this international collaboration and acknowledged. Moreover, program representatives who fulfill journal authorship guidelines are also recognized in Table 3 ). The overall rate of oral clefts is 15.4 per 10 000 births (including terminated pregnancies). The rates vary internationally, and the variation is driven mainly by the rates of cleft lip with or without cleft palate (CL±P). From the data of the 26 registries in Europe, it appears that rates of CL±P correlate directly with latitude (r = 0.61; P < .01), with higher rates in the north and lower rates in the south. This correlation is not present for cleft palate.
In areas with high overall rates of orofacial clefts, cases of cleft lip and palate, the more severe form of primary palate defects, tend to represent a higher proportion of all cases than they do in areas with lower overall rates of orofacial clefts. This is consistent with the multifactorial model, which predicts that the more common the defect in a population the higher the proportion of severe forms of that defect. Other information that is currently available from the IPDTOC includes the distribution of rates by clinical presentation of the child (isolated, multimalformed, syndrome), maternal age, gender, defect phenotype (e.g., bilateral vs unilateral cleft lip), twinning status, pregnancy outcome (e.g., termination of pregnancy), birthweights, and length of gestation. (For more information, visit http://www.who.int/ genomics/anomalies/idcfa/en and http://www.icbd.org.)
A further purpose of the international database is to stimulate the creation of specific databases of craniofacial anomalies. An International Database on Moebius Syndrome (Italy, United States, Brazil) was developed recently (for information, visit http:// www.icbd.org), and plans are being formulated for the International Surgical Departments Database of Craniofacial Anomalies, which will collect information from surgical departments in defined areas (country, region, city). More generally, a goal of IDCFA is to assemble multiple databases, each with its own methods and aims, so that they can collectively help answer a range of questions relevant to people with craniofacial anomalies, their families, and their health care providers.
PUBLIC HEALTH GENETIC RESEARCH: INTERNATIONAL OPPORTUNITIES
International collaboration in genetics provides a range of opportunities for improving public health research and prevention. For example, such collaboration can provide the fundamental molecular epidemiology of genes of public health importance, which is the basis for the study of gene-disease associations. 18 International collaboration also helps researchers assess such associations across a wider and therefore more informative range of genotype frequencies and environmental exposures than would be feasible in any particular country. At the same time, collaboration provides quick access to larger study populations, with resulting improvement in the statistical power of the study. Equity is a further consideration. In its 2002 report on genomics and world health, 19 One such successful collaboration within the framework of the Clearinghouse was supported in part by the Centers for Disease Control and Prevention's National Center on Birth Defects and Developmental Disabilities and the Italian Ministry for Research. This collaboration evaluated the 677C→T allele of 5,10 methylenetetrahydrofolate reductase, a folate-related gene, in well-defined populations from 14 areas in the Americas, Europe, Australia, and China. 20 As summarized in Table 4 , the study identified significant geographic and ethnic variation in this specific genotype, which has been associated with an increased risk for neural tube defects. 21 For example, a high frequency of homozygosity (20% or more of the population) for the variant allele was found in Mexico, northern China, and southern Italy. Ethnic variability was also remarkable, with a high frequency of homozygosity (18%) among Hispanic Americans, intermediate frequency (11%) among non-Hispanic White Americans, and low frequency (< 3%) among African Americans in a population-based sample in the Atlanta area. 20 From a practical perspective, this collaboration experienced the full range of capacities among partners. Some registries (e.g., China, Atlanta) could have entirely supported a local study, from sample collection to genetic testing and report writing, but chose to collaborate and thus, gain inclusion in a larger, stronger, and more meaningful study. Other programs (e.g., Israel, Mexico) had many of the capabilities but little funding, but, with some financial support (mainly for reagents), were able to provide more data and the participation of populations of interest. Many other programs were able to collect but not analyze samples and through this collaboration were able to participate in novel genetic studies and generate locally relevant data. Finally, some programs participated in the discussions but not in the study and thus were able to develop some knowledge in areas such as study design, sample collection and storing, quality control, and data analysis.
Ultimately, this successful collaboration provides the basis for further public health research on other genotypes of public health importance in the context of a partnership of developed and developing countries.
OTHER MONITORING AND RESEARCH ACTIVITIES
In addition to the activities summarized in this report, the Clearinghouse conducts other ongoing and systematic epidemiological assessments of birth defects (Table 1) . These include ongoing collaborative monitoring of selected conditions, performed both as rapid assessments (every 3 months) and as annual evaluations. Conditions such as Down syndrome and multiple congenital anomalies are monitored separately by ad hoc methods (e.g., using maternal age-specific analysis for Down syndrome). The annual data are used in public health research such as an assessment of birth defect rates in relation to folic acid recommendations and a retrospective case-control study on gastroschisis. After updating and further review, annual data have been used to create the World Atlas of Birth Defects, now in its second edition, to provide information on the prevalence and burden of congenital malformations worldwide. 22 Updated information on these and other resources can be found in the annual reports of the Clearinghouse (visit http:// www.icbd.org). In these and other activities, the Clearinghouse increasingly collaborates with other organizations, such as the European Surveillance of Congenital Anomalies and the National Birth Defects Prevention Network in the United States.
STRATEGIC DIRECTION
In 2004, on the occasion of the organization's 30th anniversary, under the chairmanship of one of the authors (B. B.), the ICBDMS initiated a strategic planning process in order to critically examine current activities and to redirect its efforts going forward. The strategic planning team consisted of a selective group of committed program directors with diverse opinions. As is the case with any strategic planning process, the lessons learned from past activities-both strengths and weaknesses-will be used to inform future directions.
Lessons Learned, 1974 to 2004
First, monitoring congenital anomalies and publishing the demographics of who is at risk among large populations throughout the world has been an important first step. However, going forward, surveillance of birth defects needs to become the critical activity for Clearinghouse members. The team defined "monitoring" as an activity for which the primary task is counting accurately. "Surveillance," on the other hand, begins with counting but involves systematic public health action as follow-up. This action might be etiologic research, advocacy, educating policymakers, or assessing the effectiveness of interventions such as folic acid fortification.
Second, conducting etiologic research, although an activity of some individual Clearinghouse members, has been underemphasized by the Clearinghouse as an organization. Since congenital anomalies are common-approximately 1 in 33 live births-and causes are mostly unknown, the only way to develop effective prevention strategies is to increase understanding about why congenital anomalies occur.
Third, between 1974 and 2004, the Clearinghouse had as a membership criterion that programs must monitor structural congenital anomalies. Many organizations that were effectively monitoring other common children's disabilities with high morbidity, such as prematurity or cerebral palsy, have not been part of the Clearinghouse.
Fourth, quarterly statistical surveillance and investigation of clusters of congenital anomalies, although useful services to communities, have not in 30 years of Clearinghouse operation resulted in the discovery of even one cause of any structural congenital anomaly anywhere in the world.
Strategic Direction of the Clearinghouse, 2004 Going Forward
The Clearinghouse has provided an invaluable international forum in which epidemiological data on structural congenital anomalies have been compiled, exchanged, and published. These activities will continue. However, the strategic planning team recommended the following changes for the future, subject to member ratification:
1. Surveillance rather than monitoring will be emphasized. 2. Non-Clearinghouse researchers will be invited to collaborate with Clearinghouse members to use the diverse population-based data, the core strength of Clearinghouse programs, to test important research hypotheses. 3. Surveillance programs that include children's disabilities other than structural congenital anomalies will be invited to join the Clearinghouse. 4. There will be less emphasis on quarterly statistical monitoring and more emphasis on constant communication among Clearinghouse members.
5. The name of the organization will be changed to the International Clearinghouse for Birth Defects Surveillance and Research to reflect the strategic direction. (This has been ratified and implemented.)
FINAL CONSIDERATIONS
As international priorities change and technical capacity increases, the range of activities for organizations such as the Clearinghouse appear not so much to change but rather to expand. Surveillance remains a priority and is now increasingly geared toward providing timely information for action. Primary prevention of some birth defects, which was limited 30 years ago, is today feasible with folic acid and other interventions and requires promotion and evaluation. Etiologic research, through new tools (e.g., molecular genetics), can find unique avenues for progress through registry-based international collaboration. Developing countries, where most births now occur, must be supported in their concerns relating to birth defects and genetic diseases. In a time of information explosion and Internet-based communication, international networks can help provide multilingual content and a supranational conduit for disseminating crucial information on birth defects' impact, health outcomes, and prevention.
Yet such remarkable possibilities can be made real only through a conscious investment in international collaboration. Such effort over 30 years has produced remarkable results but has been based on limited funding and much in-kind work by partner programs. This is a testament to the activity of many but hardly a policy for sustainable development.
Crucial support has come from several institutions, both governmental (e.g., the US Centers for Disease Control and Prevention, the National Institutes of Health, the Norwegian and Italian governments, the European Commission) and nongovernmental (e.g., the March of Dimes). What is needed, as we move forward in the years ahead, is a concerted and sustainable effort by the international community, through national and international agencies, to support and sustain the international activities that it considers important and thus realize the possibilities of birth defect surveillance, research, and primary prevention for the world as a whole.
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